BCL9 knockdown enhanced the survival of the xenograft mouse model of CRC and attenuated the expression of pro-angiogenic factors (e.g., CD44, and VEGF), which resulted in a reduction of tumor metastasis and angiogenesis [67]. This evidence concerns the gene BCL9 and neoplasm.